Herantis Pharma
Herantis Pharma is a Finnish clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to modulate multiple disease-relevant pathways in Parkinson's disease. The company is preparing for Phase 2 proof-of-concept trials targeted for 2027.
- Company typePublic
- Founded2008
- HeadquartersHelsinki, Finland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Herantis Pharma does
Herantis Pharma is a Finnish clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with its primary focus on Parkinson's disease. The company is headquartered in Espoo, Finland (Bertel Jungin Aukio 1, FIN-02600), is listed on Nasdaq First North Growth Market Finland under ticker HRTIS, and operates as a public limited liability company (Herantis Pharma Oyj / Plc). The company's lead product candidate is HER-096, a first-in-class blood-brain barrier penetrating peptide therapy that modulates multiple disease-relevant pathways — proteostasis, mitochondrial function, and neuroinflammation — and is administered subcutaneously. Herantis completed a Phase 1b trial in 2025 enrolling 24 Parkinson's disease patients, meeting all primary and secondary endpoints for safety and tolerability, with HER-096 achieving pharmacologically active concentrations in cerebrospinal fluid. Positive biomarker data were reported in January 2026 and presented at the AD/PD 2026 conference in Denmark in March 2026.
The business model is pre-revenue clinical-stage drug development. Herantis has no marketed products and currently raises capital through directed share issues (EUR 1.46 million in March 2022, EUR 5.2 million in February 2025, EUR 4.2 million in February 2026) supplemented by non-dilutive grants (a EUR 8.0 million Horizon Europe 2025 grant awarded February 2026). Support has also come from the EIC Fund, Michael J. Fox Foundation, and Parkinson's UK. As of the disclosed run-rate, the company has 11–50 employees and cash runway to Q1 2027, with management stating EUR 20–25 million of additional capital is needed to fund planned Phase 2 efficacy trials. Commercial GTM is not yet active; future commercialization would follow standard pharmaceutical wholesale and distribution pathways targeting early-stage Parkinson's disease patients.
Recent corporate actions include the May 2026 partnership with Indivi to integrate smartphone-based digital biomarker assessments into the Phase 2 trial, the June 2026 appointment of Dr Juha Savola as Chief Medical Officer (with prior senior clinical development experience at Spark Therapeutics, Teva, Roche, and Santhera), and positive FDA feedback finalized in June 2026 on the Phase 2a study design, with patient enrollment expected to begin soon. The Phase 2 proof-of-concept trial, planned for 2027, is targeted to enroll approximately 100 patients across Europe.
Herantis Pharma firmographics
Firmographics- Name
- Herantis Pharma
- Legal name
- Herantis Pharma Oyj
- Website
- https://herantis.com
- Company type
- Public
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Herantis Pharma is a Finnish clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to modulate multiple disease-relevant pathways in Parkinson's disease. The company is preparing for Phase 2 proof-of-concept trials targeted for 2027.
- Ownership category
- akta.pro rank
Where Herantis Pharma is headquartered
LocationHeadquarters
- HQ city
- Helsinki
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
Herantis Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pre-Revenue / Clinical Stage: Herantis Pharma is a clinical-stage biotechnology company with no current revenue. The company raises capital through equity financings and non-dilutive grants to fund drug development operations.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Herantis Pharma product offering
Product offeringCore offering
Herantis Pharma is a clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to be a disease-modifying treatment for Parkinson's disease. The therapy modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation, and is administered subcutaneously. The company has completed Phase 1b clinical trials and is preparing for Phase 2 proof-of-concept trials planned for 2027.
Product overview
Herantis Pharma is a clinical-stage biotechnology company developing disease-modifying therapies for neurodegenerative diseases, with a primary focus on Parkinson's disease. The company's lead product is HER-096, a first-in-class blood-brain barrier penetrating peptide therapy. The company has completed Phase 1b trials demonstrating safety, tolerability, and biomarker responses, and is preparing for Phase 2 proof-of-concept trials.
Differentiator
Problem solved
Functional benefit
Products and services
- HER-096 First-in-class blood-brain barrier penetrating peptide therapy for Parkinson's disease that modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation. Designed for subcutaneous administration as a disease-modifying treatment for early-stage Parkinson's disease patients, currently advancing to Phase 2 proof-of-concept trials planned for 2027.
Quantifiable outcome
- Phase 1b trial met all primary and secondary endpoints for safety and tolerability
- +2 more outcomes
Companies that use Herantis Pharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
Herantis Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Herantis Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- IndivicoreHerantis Pharma partnered with Indivi to integrate Indivi's digital biomarker platform into the upcoming Phase 2 proof-of-concept trial of HER-096 for Parkinson's disease. Indivi's platform uses smartphone-based assessments of motor and cognitive function to enable more sensitive detection of treatment-related changes compared to conventional clinical assessments. Preparations for the Phase 2 study are on track.
Scale indicators9 records
Recent moves6 records
Expansion highlights5 records
Herantis Pharma competitors and assessment
Company assessmentBroad incumbents
- AbbVie: Major pharmaceutical company with established Parkinson's franchise (Duopa) and active CNS pipeline. Potential strategic acquirer/partner for differentiated Parkinson's assets like HER-096.
- Roche: Large pharmaceutical company with major CNS franchise and active Parkinson's disease programs (including prasinezumab partnership with Prothena). Logical strategic acquirer/partner for HER-096.
Emerging players
- Cerevel Therapeutics: Neuroscience-focused clinical biotech acquired by AbbVie in 2024 for $8.7B. Comparable CNS clinical-stage profile and disease-modifying approach, illustrating large-pharma BD appetite for differentiated CNS pipelines.
Direct peers
- Acadia Pharmaceuticals: Specialty CNS pharma commercializing Nuplazid (pimavanserin) for Parkinson's disease psychosis. Comparable CNS/Parkinson's therapeutic focus, though at a more advanced commercial stage.
- Denali Therapeutics: Biotech developing engineered BBB-crossing therapeutics for neurodegenerative diseases including Parkinson's. Highly comparable technology approach (BBB delivery) and indication focus.
- Prothena Corporation: Clinical-stage biotech developing disease-modifying therapies for Parkinson's disease (e.g., prasinezumab, partnered with Roche). Closely comparable to Herantis as a CNS-focused biotech targeting Parkinson's progression rather than symptoms.
- Sage Therapeutics: Specialty CNS biotech focused on neurological disorders. Recently acquired by Biogen in 2024, demonstrating the BD exit path for small CNS biotechs with differentiated clinical assets.
- Voyager Therapeutics: Clinical-stage gene therapy company developing AAV-based treatments for Parkinson's disease and other CNS disorders. Direct peer in CNS/Parkinson's clinical development with similar size and stage.
- Prevail Therapeutics (Eli Lilly): Gene therapy company developing PR001 for Parkinson's disease with GBA1 mutations. Acquired by Eli Lilly in 2021, illustrating BD exit dynamics for Parkinson's gene therapy/peptide approaches.
- Anavex Life Sciences: Clinical-stage biotech developing CNS therapies for neurodegenerative and neurodevelopmental disorders. Comparable size, clinical-stage profile, and CNS disease-modifying mechanism approach.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Customer concentration
Herantis Pharma social profiles
Digital presenceHerantis Pharma compliance and trust
Trust signalCompliance1 record
Herantis Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Herantis Pharma leadership team
Management profileNumber of profiles
Profiles4 records
Herantis Pharma funding detail
Funding detailFunding overview
Funding rounds10 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Herantis Pharma M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Herantis Pharma
What does Herantis Pharma do?
Herantis Pharma is a clinical-stage biotechnology company developing HER-096, a first-in-class blood-brain barrier penetrating peptide therapy designed to be a disease-modifying treatment for Parkinson's disease. The therapy modulates multiple disease-relevant pathways including proteostasis, mitochondrial function, and neuroinflammation, and is administered subcutaneously. The company has completed Phase 1b clinical trials and is preparing for Phase 2 proof-of-concept trials planned for 2027.
Is Herantis Pharma a public or private company?
Herantis Pharma is a public company. It is classified as public and is currently operating.
When was Herantis Pharma founded?
Herantis Pharma was founded in 2008. It employs 11 to 50 people.
Where is Herantis Pharma based?
Herantis Pharma is headquartered in Helsinki, Finland, in the Europe region.
How does Herantis Pharma make money?
One revenue line is on record: pre-Revenue / Clinical Stage.
Who are Herantis Pharma's main competitors?
Broad incumbents on record are AbbVie and Roche. Cerevel Therapeutics is listed as an emerging player. Direct peers are Acadia Pharmaceuticals, Denali Therapeutics, Prothena Corporation, Sage Therapeutics, Voyager Therapeutics, Prevail Therapeutics (Eli Lilly) and Anavex Life Sciences.
Does Herantis Pharma have an API?
No public API is recorded for Herantis Pharma.